CLNN
Consumer DefensiveClene Inc.
$5.76
$-0.01 (-0.17%)
Jan 5, 2026
Price History (1Y)
Analysis
Clene Inc. is a consumer defensive company operating in the packaged foods industry with a market capitalization of $59.52M. The company has 75 employees and its revenue over the trailing twelve months (TTM) stands at $214,000. The company's financial health is marked by significant losses, with a net income of -$30,496,000 over the TTM period. Its gross margin is 82.2%, but it has negative operating and profit margins, respectively -37653.3% and 0.0%. The company's return on assets (ROA) is -56.2%, indicating substantial losses relative to its assets. Clene Inc.'s balance sheet shows $7.92M in cash and $21.31M in debt. The valuation context for Clene Inc. is characterized by a negative forward price-to-earnings ratio of 2.79, a negative price-to-book ratio of -4.76, and a high price-to-sales ratio of 278.15. The company's revenue growth over the past year (YoY) was -82.8%, indicating significant decline in sales.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Visit website →Key Statistics
- Market Cap
- $59.52M
- P/E Ratio
- N/A
- 52-Week High
- $13.50
- 52-Week Low
- $2.28
- Avg Volume
- 176.82K
- Beta
- 0.87
Company Info
- Industry
- Packaged Foods
- Exchange
- NCM
- Country
- United States
- Employees
- 75